Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. [electronic resource]
Producer: 20070302Description: 176-84 p. digitalISSN:- 0264-410X
- Adjuvants, Immunologic -- administration & dosage
- Adult
- Animals
- Antibodies, Protozoan -- blood
- Double-Blind Method
- Drug Combinations
- Female
- Humans
- Kenya
- Lipid A -- administration & dosage
- Malaria Vaccines -- administration & dosage
- Malaria, Falciparum -- immunology
- Male
- Merozoite Surface Protein 1 -- chemistry
- Middle Aged
- Plasmodium falciparum -- immunology
- Saponins -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.